Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Nasopharyngeal Carcinoma 51Uterine Cervical Neoplasms 44Lung Neoplasms 38Esophageal Neoplasms 32Head and Neck Neoplasms 28Esophageal Squamous Cell Carcinoma 28Squamous Cell Carcinoma of Head and Neck 22Stomach Neoplasms 20Breast Neoplasms 16Small Cell Lung Carcinoma 15Recurrence 12Neoplasm Metastasis 12Nasopharyngeal Neoplasms 12Carcinoma, Squamous Cell 10Ovarian Neoplasms 9Central Nervous System Neoplasms 9Neuroblastoma 8Lymphoma, Large B-Cell, Diffuse 8Pancreatic Neoplasms 7Lymphoma 7Hypopharyngeal Neoplasms 7Triple Negative Breast Neoplasms 6Oropharyngeal Neoplasms 6Neoplasms 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Resectable Biliary Tract Cancer × Cisplatin × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡